Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

Ramanan Laxminarayan, Mead Over, David L. Smith

Research output: Contribution to journalArticle

Abstract

Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.

Original languageEnglish (US)
Pages (from-to)325-336
Number of pages12
JournalHealth Affairs
Volume25
Issue number2
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Antimalarials
subsidy
Artemisinins
economic value
Chloroquine
Malaria
Parasites
Economics
artemisinine
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)
  • Health(social science)
  • Health Professions(all)
  • Health Policy

Cite this

Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? / Laxminarayan, Ramanan; Over, Mead; Smith, David L.

In: Health Affairs, Vol. 25, No. 2, 03.2006, p. 325-336.

Research output: Contribution to journalArticle

Laxminarayan, Ramanan ; Over, Mead ; Smith, David L. / Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?. In: Health Affairs. 2006 ; Vol. 25, No. 2. pp. 325-336.
@article{0cd53b5b66944503b15e5ff86a0863da,
title = "Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?",
abstract = "Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.",
author = "Ramanan Laxminarayan and Mead Over and Smith, {David L.}",
year = "2006",
month = "3",
doi = "10.1377/hlthaff.25.2.325",
language = "English (US)",
volume = "25",
pages = "325--336",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "2",

}

TY - JOUR

T1 - Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

AU - Laxminarayan, Ramanan

AU - Over, Mead

AU - Smith, David L.

PY - 2006/3

Y1 - 2006/3

N2 - Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.

AB - Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.

UR - http://www.scopus.com/inward/record.url?scp=33645673826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645673826&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.25.2.325

DO - 10.1377/hlthaff.25.2.325

M3 - Article

C2 - 16522574

AN - SCOPUS:33645673826

VL - 25

SP - 325

EP - 336

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 2

ER -